# MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care

Study · id `cardio:ct-nct05287191` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05287191](<https://clinicaltrials.gov/study/NCT05287191>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05287191

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05287191. Randomized; single masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2025-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05287191, source copy `cardio:ctgov-nct05287191-2024-04-25`, retrieved 2026-10-26)
- Started: 2022-01-05 (actual) (ClinicalTrials.gov record NCT05287191, source copy `cardio:ctgov-nct05287191-2024-04-25`, retrieved 2026-10-26)
- Primary completion: 2025-10-31 (anticipated) (ClinicalTrials.gov record NCT05287191, source copy `cardio:ctgov-nct05287191-2024-04-25`, retrieved 2026-10-26)
- Completion: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT05287191, source copy `cardio:ctgov-nct05287191-2024-04-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT05287191, source copy `cardio:ctgov-nct05287191-2024-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05287191-2024-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
- Acronym: MAGNAM
- Condition: Atrial Fibrillation New Onset
- Intervention (Drug): Magnesium sulfate and then Digoxin
- Intervention (Drug): Amiodarone
- Lead sponsor: Sunnybrook Health Sciences Centre
- Lead sponsor class: OTHER
- Collaborator: Sunnybrook Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Amiodarone (`cardio:amiodarone`)
- Registry lists this organization as the lead sponsor: Sunnybrook Health Sciences Centre (`cardio:org-sunnybrook-health-sciences-centre`)
- Registry lists this organization as a collaborator: Sunnybrook Research Institute (`cardio:org-sunnybrook-research-institute`)

## Provenance

Content hash: a6217ea5117405f59a9ad45944c5633d17508035e753138b097bcbe8063b2a44
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
